Ex vivo transcriptional alterations in glutamatergic transmission in patients with multiple sclerosis

Key Points

• Transcriptional alterations were observed, impacting glutamatergic transmission in multiple sclerosis patients, indicating disease-related changes.
• Key evidence shows significant changes in 5 transcriptional biomarkers linked to glutamatergic activity.
• Analysis involved ex vivo assessments from patients diagnosed with multiple sclerosis, correlating with disease progression.
• These findings highlight potential biomarkers that may improve understanding of multiple sclerosis' impact on neurotransmission.